真实世界实践中外周动脉腔内血运重建后利伐沙班的有效性与安全性
基于Merative MarketScan数据库的回顾性队列研究纳入2017至2024年接受下肢外周血管介入的88,792例PAD患者,仅1.5%在术后30天内处方低剂量利伐沙班,其中43%依从。
要点
- 真实世界中PVI后低剂量利伐沙班使用率仅1.5%,1年内依从率43%。
- 依从低剂量利伐沙班者1年大截肢风险显著降低70%。
- 低剂量利伐沙班使用与出血并发症风险增加相关。
核心结论
- VOYAGER PAD发表后真实世界低剂量利伐沙班使用率仍低且依从性不一。
- 若维持依从,PVI后真实世界临床结局与临床试验相似。
研究设计与样本
- 回顾性队列研究,使用Merative MarketScan数据库识别2017至2024年接受下肢PVI的40至90岁患者。
- 共识别88,792例患者,其中1285例(1.5%)在PVI后30天内处方低剂量利伐沙班。
- 排除接受治疗性抗凝的患者,采用倾向子类加权分析和Cox比例风险模型。
主要发现
- 处方低剂量利伐沙班的1285例中仅547例(43%)在血运重建后1年内依从(PDC≥80%)。
- 非依从患者MALE结局无显著改善。
临床怎么用
- PVI后应考虑评估患者是否适合低剂量利伐沙班并强调依从性以降低大截肢风险。
- 处方低剂量利伐沙班时需权衡出血风险增加。
局限性
- 回顾性队列设计可能存在残余混杂。
- 低剂量利伐沙班组样本量较小(1285例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The VOYAGER PAD clinical trial demonstrated that low-dose rivaroxaban (LDR; 2.5 mg twice daily) reduces major adverse limb events (MALE) at the expense of increased bleeding rates in patients undergoing lower extremity revascularization for peripheral artery disease (PAD). However, it is unclear whether LDR therapy is associated with similar outcomes in real-world practice. This retrospective cohort study was designed to evaluate the effectiveness and safety of LDR therapy following peripheral vascular intervention (PVI) for patients with PAD. METHODS: The Merative MarketScan database was used to identify patients 40 to 90 years old who underwent lower extremity PVI between 2017 and 2024. Pharmacy claims were used to identify LDR use within 30 days post-PVI and patient adherence to therapy within 1 year while excluding those receiving therapeutic anticoagulation. For patients prescribed LDR, the proportion of days covered (PDC) was determined and those greater or equal to 80% of PDC were classified as adherent. After performing a propensity-subclass weighted analysis on the use of LDR, we used Cox proportional hazards models to estimate the risk-adjusted incidence of MALE and bleeding complications following PVI. RESULTS: We identified 88,792 patients, of which 1285 (1.5%) were prescribed LDR within 30 days post-PVI. However, only 547 of these patients (43%) were adherent to LDR within the year after revascularization. After propensity weighted analysis, patients on LDR were well-matched to those not on therapy based on age, sex, comorbidities, and demographics. Although non-adherent patients had no significant improvement in MALE outcomes, those adherent to LDR therapy had a 70% lower likelihood of major amputation at 1 year after revascularization (hazard ratio, 0.30; 95% confidence interval, 0.10-0.91; P = .03). There was an increased likelihood of experiencing a bleeding complication (hazard ratio, 1.85; 95% confidence interval, 1.24-2.76; P = .002) associated with LDR use relative to the non-LDR control group. CONCLUSIONS: Following the publication of VOYAGER PAD, the use of LDR remains low, and patient adherence is variable. However, clinical outcomes in real-world practice are similar if adherence to LDR is maintained following PVI. Further work is needed to define the optimal patients with PAD who should receive LDR following revascularization.
引用
- Schurman AM, Horns JJ, Weaver ML, et al. Effectiveness and safety of rivaroxaban following peripheral arterial endovascular revascularization in real-world practice. J Vasc Surg. 2026. PMID: 41786009. doi:10.1016/j.jvs.2026.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。